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EDITORIAL
The Heart Team, TAVI and 
natural selection
“The slow one now will later be fast... for the times they are a-changin” - Bob Dylan
The announcement in 2002 that Alan Cribier had performed the first Transcatheter Aortic Valve 
Implantation (TAVI) ranked right up there with the announcement that the first heart transplant 
had been performed by Chris Barnard, or the announcement that Andreas Gruentzig had 
performed the first coronary angioplasty. At the time we rightly viewed this as an exciting 
breakthrough in the management of patients with aortic stenosis and had little reason to 
anticipate that perhaps the major challenge for TAVI still lay ahead. We now know that we can 
replace the aortic valve via a percutaneous technique. We also know that we can achieve 
comparable results to surgical aortic valve replacement with this percutaneous technique. To 
prove this we have primarily applied the technique to the elderly, high risk surgical candidates, 
often considered inoperable. In doing so we have prolonged the lifespan and/or improved the 
quality of life of a number of patients. However, in a fair number of patients we have achieved 
neither a longer life, nor a better quality of life. The challenge to select the patient who will 
benefit from a TAVI may be more difficult to achieve than the technical challenge of performing 
this amazing procedure.
The innovation of TAVI has empowered us with the ability to successfully treat advanced aortic 
stenosis in patients of advanced age, often with advanced co-morbidities. However, the sobering 
reality is that a substantial portion of these patients will not benefit from this procedure. The 
challenge that we have not yet mastered is to select the patient who will benefit from the 
procedure whilst advising against the procedure in patients who will not benefit, thus avoiding 
futility and potential harm.
This issue of SA Heart features an important consensus statement by the South African 
Cardiovascular Society of Cardiovascular Intervention (SASCI) and the Society of Cardiothoracic 
Surgeons of South African (SCTSSA), providing guidance for practitioners performing TAVI. 
They address the establishment of a TAVI team, the requirements of the Multidisciplinary Heart 
Team (MDT) and they also list the indications and contra-indications for TAVI. The section 
dealing with patient selection is, perhaps understandably, glossed over, stating only that the 
requirements are:  a.) proof of severe symptomatic aortic valve stenosis and b.) patient evalua-
tion by a MDT. It is the latter recommendation that is fraught with difficulty. One of the contra-
indications for TAVI listed in the consensus statement is a predicted life expectancy of less than 
a year. A very logical recommendation that most of us would argue is medically, morally and 
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ethically sound. Consider now the 1-year outcome data report for patients in the CoreValve US Pivotal 
Extreme and High Risk trials.(1) Thirty percent were dead at 1 year. If one knew that up-front, TAVI would 
have been contra-indicated in a third of these patients. Add to that the fact that fifty percent of the 
patients in these trials had a poor outcome (defined as death, a poor quality of life or a worsening of 
quality of life compared to the pre-TAVI status), one can only wonder what patients would say if they 
are told, when providing informed consent, that a favourable outcome at 1 year could best be predicted 
by flipping a coin. Of course one must immediately take cognisance of the fact that these results were 
achieved in a geriatric population (average age 83.3 years) considered to be at high risk or extreme risk. 
The future of this procedure may well involve younger patients at significantly lower risk. However, the 
fact remains that while we can perform a TAVI in very old patients at very high risk, we have yet to 
master the challenge of selecting the right patient to ensure that we do not cross the line that would lead 
to futility.
The dilemma that the MDT face when evaluating a patient being considered for a TAVI is that the very 
reasons giving rise to the patient not being considered for surgical aortic valve replacement (such as 
advanced lung disease, advanced renal disease, advanced age and frailty) are also the best predictors of 
a poor outcome with TAVI. Recent publications are indicating the direction we have to take to select 
patients appropriately for TAVI.(1) Clearly the decision must be taken by a MDT. The MDT must include 
sufficient expertise beyond the opinion of the cardiac surgeon and cardiologist involved in the pro-
cedure. Recommendations are that the MDT should include the primary or treating cardiologist, the 
interventional cardiologist, the cardiac surgeon, the anaesthesiologist, imaging specialists, rehabilitation 
specialists, advanced care nurses, social workers and administrators.(2) The decision must be based on a 
number of indicators, in addition to the standard surgical risk indicators, such as the Society of Thoracic 
Surgeons (STS) mortality risk score including lung function, renal function, age, indicators of frailty (such 
as inactivity and unexplained weight loss) and indicators of disability or inability to perform activities of 
daily living (such as dressing and feeding independently). Studies suggest that it is not necessary to 
perform cumbersome or complex tests such as grip strength or walk speed although specific tests such 
as a 6 minute walk test as an indicator of functional impairment, or a serum albumin as an indicator of 
catabolism or malnutrition, may improve the accuracy of predicting.
Incredible developments in treating advanced cardiac disease are being added to the armamentarium of 
the cardiologist at an impressive rate. Device therapy allows us to prevent a bradycardic death by 
implanting a pacemaker, to prevent a tachycardic death by implanting a defibrillator, to prevent a 
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haemodynamic death by implanting an aortic valve without surgery. We can improve the 
outcome and the quality of life of selected patients with end-stage heart failure with a cardiac 
resynchronisation therapy (CRT) device. The word “selected” is perhaps the key word here. 
Many of the conditions and devices listed are being used to treat patients with advanced 
pathology, often of a degenerative and progressive nature. The ability to prolong life and to 
improve the quality of life is a finite one. The next leap in our ability to treat patients with 
cardiovascular disease may not be another wonderful device, but rather the ability to accurately 
select patients who will, or will not, benefit from a particular therapeutic option.
When Bob Dylan sang “The slow one now will later be fast” he was not necessarily referring to 
very old patients with advanced cardiac disease. However, he may well have had our profession 
in mind when he sang “for the times they are a-changin”.
